Skip to main content
. 2024 Dec 2;13:88. doi: 10.1186/s40249-024-01262-9

Fig. 2.

Fig. 2

Anti-PGL-I IgM in NEC and MB leprosy patients. Serum samples (A) of NEC (n = 210) and MB leprosy patients (n = 133) and FSB samples (B) of NEC (n = 500) and MB leprosy patients (n = 47) were examined using the PGL-I QURapid. Left panels: R-values for anti-PGL-I IgM in NEC and MB leprosy patients; right panels: corresponding ROC curves. R-values (Y-axis) were calculated by dividing the peak area of the test line (T) by the peak area of the flow control line (FC). A Mann–Whitney U test was performed to determine the statistical significance between the two groups (****P ≤ 0.0001). AUC Area Under the Curve, NEC non-endemic controls, MB multibacillary, ROC receiver operating characteristic